Anebulo Pharmaceuticals (ANEB) Free Cash Flow (2020 - 2025)
Anebulo Pharmaceuticals (ANEB) posted quarterly Free Cash Flow of -$1.3 million for Q4 2025, up 6.58% year-over-year from -$1.2 million in Q4 2024, and down 3.15% quarter-over-quarter from -$1.3 million in Q3 2025.
Anebulo Pharmaceuticals (ANEB) Free Cash Flow (2020 - 2025) Analysis & Trends
Anebulo Pharmaceuticals (ANEB) has reported Free Cash Flow for 6 consecutive years, with -$1.3 million the latest figure, recorded in Q4 2025.
- In Q4 2025, Free Cash Flow rose 6.58% year-over-year to -$1.3 million; the TTM figure through Dec 2025 stood at -$5.8 million (up 12.12% YoY), while the FY2025 annual figure was -$6.3 million, up 21.52% from the prior year.
- Free Cash Flow fell to -$1.3 million in Q4 2025 per ANEB's latest filing, from -$1.3 million in the prior quarter.
- Across five years, Free Cash Flow topped out at -$777902.0 in Q3 2021 and bottomed at -$3.5 million in Q2 2021.
- Historically, Free Cash Flow has averaged -$1.8 million across 5 years, with a median of -$1.7 million in 2024.
- Annual changes were most pronounced in 2021 — Free Cash Flow plunged 476.41% — and 2022, when it surged 42.83%.
- Anebulo Pharmaceuticals' Free Cash Flow stood at -$1.2 million in 2021, then plunged by 117.68% to -$2.6 million in 2022, then soared by 30.49% to -$1.8 million in 2023, then grew by 22.49% to -$1.4 million in 2024, then gained by 6.58% to -$1.3 million in 2025.
- Business Quant data shows ANEB's Free Cash Flow at -$1.3 million in Q4 2025, -$1.3 million in Q3 2025, and -$1.7 million in Q2 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Free Cash Flow (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 1.01 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 572.80 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | -563.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 437.80 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 292.04 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 433.84 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | -95.09 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 477.44 Mn |
| 10 | Anebulo Pharmaceuticals | 16.43 Mn | 16.43 Mn | - | -1.31 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | -1.31 Mn |
| Dec 31, 2025 | -1.31 Mn |
| Sep 30, 2025 | -1.27 Mn |
| Sep 30, 2025 | -1.27 Mn |
| Jun 30, 2025 | -1.65 Mn |
| Jun 30, 2025 | -1.65 Mn |
| Mar 31, 2025 | -1.60 Mn |
| Mar 31, 2025 | -1.60 Mn |
| Dec 31, 2024 | -1.41 Mn |
| Dec 31, 2024 | -1.41 Mn |
| Sep 30, 2024 | -1.69 Mn |
| Sep 30, 2024 | -1.69 Mn |
| Jun 30, 2024 | -2.05 Mn |
| Jun 30, 2024 | -2.05 Mn |
| Mar 31, 2024 | -1.50 Mn |
| Mar 31, 2024 | -1.50 Mn |
| Dec 31, 2023 | -1.81 Mn |
| Dec 31, 2023 | -1.81 Mn |
| Sep 30, 2023 | -2.73 Mn |
| Sep 30, 2023 | -2.73 Mn |